MDT

81.38

-1.36%↓

VEEV

209.53

-2.83%↓

A

99.53

-2.76%↓

WBA

10.84

-0.37%↓

CHE

563.06

-2.85%↓

MDT

81.38

-1.36%↓

VEEV

209.53

-2.83%↓

A

99.53

-2.76%↓

WBA

10.84

-0.37%↓

CHE

563.06

-2.85%↓

MDT

81.38

-1.36%↓

VEEV

209.53

-2.83%↓

A

99.53

-2.76%↓

WBA

10.84

-0.37%↓

CHE

563.06

-2.85%↓

MDT

81.38

-1.36%↓

VEEV

209.53

-2.83%↓

A

99.53

-2.76%↓

WBA

10.84

-0.37%↓

CHE

563.06

-2.85%↓

MDT

81.38

-1.36%↓

VEEV

209.53

-2.83%↓

A

99.53

-2.76%↓

WBA

10.84

-0.37%↓

CHE

563.06

-2.85%↓

Search

Anavex Life Sciences Corp

Abierto

SectorSalud

8.84 -0.56

Resumen

Variación precio

24h

Actual

Mínimo

8.68

Máximo

9.19

Métricas clave

By Trading Economics

Ingresos

-491K

-12M

BPA

-0.14

Empleados

42

EBITDA

-1.8M

-14M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+218.44% upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

776M

Apertura anterior

9.4

Cierre anterior

8.84

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

144 / 385 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Anavex Life Sciences Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 abr 2025, 01:45 UTC

Ganancias

Preview -- Barron's

18 abr 2025, 15:57 UTC

Principales Movimientos del Mercado

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

20 abr 2025, 22:32 UTC

Principales Noticias

Stocks Poised for Lower Open -- Barrons.com

20 abr 2025, 18:43 UTC

Principales Noticias

Chicago Fed's Goolsbee Has a Warning About Independence -- Barrons.com

20 abr 2025, 18:00 UTC

Principales Noticias

Tesla, Alphabet, Verizon, Chipotle, IBM, Boeing, and Many More Stocks to Watch This Week -- Barrons.com

20 abr 2025, 13:00 UTC

Principales Noticias

Airbus Promised a Green Aircraft. That Bet Is Now Unraveling. -- WSJ

20 abr 2025, 06:00 UTC

Principales Noticias

Foreign Stocks Are Beating the U.S. Market. Here's How Much You Should Have in Your Portfolio. -- Barrons.com

20 abr 2025, 03:00 UTC

Principales Noticias

Putin's War Economy Can't Escape Trump's Trade Blitz -- WSJ

20 abr 2025, 02:00 UTC

Principales Noticias

Who Will Pay the Price for Trump's Economic Goals? -- WSJ

19 abr 2025, 02:00 UTC

Principales Noticias

Tomatoes Become One of the First Everyday Casualties of Trade War -- WSJ

19 abr 2025, 02:00 UTC

Principales Noticias

Beijing Stokes Patriotic Fervor and Blames U.S. for Trade War -- WSJ

18 abr 2025, 20:42 UTC

Adquisiciones, fusiones, absorciones

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 abr 2025, 20:32 UTC

Principales Noticias

Trump to Replace Acting IRS Commissioner -- 2nd Update

18 abr 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

18 abr 2025, 19:52 UTC

Charlas de Mercado

Correction to Aluminum Fee Rising Slower Than Forecast Article

18 abr 2025, 19:40 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

18 abr 2025, 19:40 UTC

Charlas de Mercado

Aluminum Fee Rising Slower Than Forecast From Tariff -- Market Talk

18 abr 2025, 18:51 UTC

Ganancias

Netflix Has Made Several Risky Bets. Earnings Show They've Paid Off. -- Barrons.com

18 abr 2025, 18:40 UTC

Adquisiciones, fusiones, absorciones

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 abr 2025, 18:29 UTC

Charlas de Mercado

Shorter Duration Seen as Way to Shield Portfolio From Political Turbulence -- Market Talk

18 abr 2025, 18:21 UTC

Principales Noticias

Ford Halts Shipments of F-150s and Other Models to China -- WSJ

18 abr 2025, 17:31 UTC

Principales Noticias

Trump to Replace Acting IRS Commissioner -- WSJ

18 abr 2025, 17:24 UTC

Adquisiciones, fusiones, absorciones

Capital One's Discover Takeover Gets the Green Light. The Two Will Create the 6th-Largest U.S. Bank. -- Barrons.com

18 abr 2025, 17:22 UTC

Adquisiciones, fusiones, absorciones

Capital One's $35 Billion Discover Takeover Clears Final Approvals -- Barrons.com

18 abr 2025, 16:00 UTC

Principales Noticias

Trump's Trade War Threatens One of America's Top Energy Exports -- WSJ

18 abr 2025, 15:53 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Bill Ackman Teases Prospect of Uber, Hertz Partnership -- Update

18 abr 2025, 15:46 UTC

Ganancias

Tech's Problems in China Are Getting Worse. These Companies Are Most at Risk. -- Barrons.com

18 abr 2025, 15:10 UTC

Charlas de Mercado
Ganancias

Netflix Momentum Likely To Continue Thanks To Growing Subscriber Base -- Market Talk

18 abr 2025, 14:46 UTC

Ganancias

Tech Earnings Have Good News for Chip Stocks, So Far. And 1 Warning. -- Barrons.com

18 abr 2025, 14:24 UTC

Charlas de Mercado
Ganancias

Netflix Still Has Room to Add Subscribers -- Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp Esperado

Precio Objetivo

By TipRanks

218.44% repunte

Estimación a 12 meses

Media 28.5 USD  218.44%

Máximo 42 USD

Mínimo 15 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.68 / 8.98Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

144 / 385 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.